PubMedCrossRef 3 Portela A, Esteller M: Epigenetic modifications

PubMedCrossRef 3. Portela A, Esteller M: Epigenetic modifications and human

disease. Nat Biotechnol 2010, 28:1057–1068.PubMedCrossRef 4. Wong JJ, Hawkins NJ, Ward RL: Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007, 56:140–148.PubMedCrossRef 5. Selleckchem R428 Matsubara Adriamycin cost N: Promoter hypermethylation and CpG island methylator phenotype in colorectal carcinogenesis. Gan To Kagaku Ryoho 2010, 37:1659–1664.PubMed 6. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998, 95:8698–8702.PubMedCrossRef 7. Momparler RL: Cancer epigenetics. Oncogene 2003, 22:6479–6483.PubMedCrossRef 8. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37–50.PubMedCrossRef 9. Burdge GC, Lillycrop KA: Nutrition, epignetics, and developmental screening assay plasticity: implications for understanding human disease. Ann Rev Nutr 2010, 30:315–339.CrossRef 10. Li Y, Tollefsbol TO: Impact on DNA methylation in cancer prevention and therapy by

bioactive dietary components. Curr Med Chem 2010, 17:2141–2151.PubMedCrossRef 11. Razin A, Riggs AD: DNA methylation and gene function. Science 1980, 210:604–610.PubMedCrossRef 12. Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 2000, 9:2395–2402.PubMedCrossRef 13. Hermann A, Gowher H, Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004, 61:2571–2587.PubMedCrossRef 14. Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 6:465–476.CrossRef 15. Riggs AD, Pfeifer GP: X-chromosome inactivation and cell memory. Trends genet 1992, 8:169–174.PubMed 16. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683–692.PubMedCrossRef 17. Greger V, Debus N, Lohmann D, Höpping W, Passarge E, Horsthemke B: Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum Genet 1994, 94:491–496.PubMedCrossRef 18. Jones PA, Baylin SB: The

fundamental Tolmetin role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415–428.PubMedCrossRef 19. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683–692.PubMedCrossRef 20. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6:107–116.PubMedCrossRef 21. Fleuriel C, Touka M, Boulay G, Guerardel C, Rood BR, Leprince D: HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumours. Int J Biochem Cell Biol 2009, 41:26–33.PubMedCrossRef 22. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Esteller N, Baylin SB, Herman JG: Transcriptional silencing of the p73 gene in acute lymphoblastic leukaemia and Burkitt’s lymphoma is associated with 5′CpG island methylation. Cancer Res 1999, 59:3352–3356.PubMed 23.

Related posts:

  1. J Immunol Methods 2005, 298: 61–72 PubMedCrossRef 19 Lin W, Vosk
  2. Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis
  3. Gastroenterology 2005, 128:1229–1242 PubMedCrossRef 11 Torres LE
  4. Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
  5. J Cell Physiol 2006, 207:520–529 PubMedCrossRef

    8 Caloge
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>